Sanofi's total sales grew 6.9% to €8,349 million. Excluding Genzyme, sales were down 4.0% reflecting €778 million of sales lost due to generic competition vs. Q2 2010. Growth platforms grew by 9.5% and including Genzyme accounted for 65.2% of total sales.

Sales of the Bayer Group grew by 0.8 percent in the second quarter to EUR 9,252 million (Q2 2010: EUR 9,179 million). The currency- and portfolio-adjusted (Fx & portfolio adj.) increase was 5.4 percent. Business performance in the emerging markets made an above-average contribution to this development.

Amgen (NASDAQ: AMGN) reported total revenue increased 4 percent during the second quarter of 2011 to $3,959 million versus $3,804 million in the second quarter of 2010. Total product sales increased 8 percent in the second quarter of 2011 to $3,893 million versus $3,613 million in the second quarter of 2010.

AstraZeneca's revenue in the second quarter was down 2 percent at CER, but was up 3 percent on an actual basis as a result of the positive impact of exchange rate movements. This global revenue performance reflects government price interventions as well as the impact of more than $0.5 billion in revenue lost to generic competition, with the impact from generics in the US and Rest of World broadly similar.

Roche and the Salzburg Festival are celebrating the fifth- anniversary of their collaboration this year. Once again, as in the past years of cooperation, students of the sciences, art and music of 34 different nationalities will come together in Salzburg

Total revenues of the Merck Group increased 16% to € 2,555 million in the second quarter from € 2,208 million in the year-ago quarter, boosted by the July 2010 acquisition of the Millipore Corporation.

For the first time, Eli Lilly and Company (NYSE: LLY) employees worldwide can donate to more than 800 grassroots projects across the globe and have their donations matched by the Eli Lilly and Company Foundation - doubling the value and impact of each employee's charitable contribution.